Citius Pharma Reports Q2 Revenue, Secures $26.5M+ Financing, Extends Runway
CTXR sits 22% above its 52-week low of $0.57.
Summary
Citius Pharmaceuticals reported Q2 FY2026 results with $1.7 million in product revenue and announced securing over $26.5 million in new financing, extending its cash runway through November 2026.
Key Events · Earnings and Guidance · CTXR
-
Q2 FY2026 Financial Results
Reported $1.7 million in net product revenue from LYMPHIR, with an 80% gross margin. The net loss was $21.2 million, or $(0.95) per share.
-
Significant Financing Secured
Citius Pharma completed a $5 million registered direct offering. Its subsidiary, Citius Oncology, secured an additional $11.5 million from warrant exercises and an initial $10 million from a $25 million debt facility, totaling over $26.5 million in new capital.
-
Cash Runway Extended
The combined financing is expected to fund operations through November 2026, addressing immediate liquidity concerns highlighted by a prior going concern warning.
-
LYMPHIR Commercial Progress
The company reported strong early commercial momentum for LYMPHIR, with 83% of target accounts on formulary review and near 100% payer coverage. Initial shipments to Europe have also commenced.
Analysis · CTXR · Life Sciences
Citius Pharmaceuticals reported its Q2 FY2026 results, marking initial product revenue of $1.7 million from its LYMPHIR launch. Crucially, the company and its subsidiary Citius Oncology secured over $26.5 million in new financing, including a $5 million registered direct offering, $11.5 million from warrant exercises, and an initial $10 million from a debt facility. This capital infusion extends the company's cash runway through November 2026, providing critical liquidity given its prior going concern warning. The reported net loss of $21.2 million for the quarter was significantly impacted by a $19.7 million one-time contract cancellation charge.
At the time of this filing, CTXR was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $0.57 to $2.48. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.